Nymox Pharmaceutical (NYMXF) AI Stock Analysis

• Market Cap: $11.18M
• Dividend Yield: N/A
• Average Volume (3M): 13.26K
• Price to Earnings (P/E): ―
• Beta (1Y): -399.63
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 93,540,140
• 10 Day Avg. Volume: 6,981
• 30 Day Avg. Volume: 13,262
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Nymox Pharmaceutical faces substantial financial challenges as reflected by its persistent losses and negative equity. The technical analysis suggests a bearish trend, and the valuation indicates a lack of earnings, contributing to a low stock score.

Nymox Pharmaceutical Business Overview & Revenue Model

Company Description

Nymox Pharmaceutical Corporation (NYMXF) is a biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of unmet medical needs in the aging population. The company primarily operates in the biotechnology and pharmaceutical sectors. Its core products include investigational drugs aimed at treating benign prostatic hyperplasia (BPH) and other aging-related conditions, with a strong focus on its lead product candidate, NX-1207.

How the Company Makes Money

Nymox Pharmaceutical Corporation makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials in the hope of achieving regulatory approval, which would allow it to market and sell these drugs. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and eventual product sales upon approval. Additionally, Nymox may receive milestone payments and royalties from partners who collaborate in the development and commercialization of its products. However, as a company focused on research and development, it may not have significant revenue until its products are approved and commercialized.

Nymox Pharmaceutical Financial Statement Overview

Summary

Nymox Pharmaceutical's financials reveal significant challenges, including persistent losses, negative equity, and cash flow issues, posing substantial risks without clear revenue or profit growth.

Income Statement

Nymox Pharmaceutical has consistently reported negative revenue, gross profit, and net income over the years, highlighting significant operational challenges. The absence of revenue growth combined with high negative EBIT and EBITDA margins indicates severe profitability issues and a lack of revenue generation capabilities.

Balance Sheet

The company has negative stockholders' equity, indicating more liabilities than assets, which is a significant financial risk. The debt-to-equity ratio is not calculable due to negative equity, but the consistent increase in total liabilities and reduction in assets suggests increasing financial instability.

Cash Flow

Nymox has consistently experienced negative operating cash flow, indicative of cash burn without sufficient operational income. Furthermore, free cash flow remains negative, reflecting a lack of capital sufficiency for reinvestment or debt reduction. The company relies heavily on financing activities to meet its cash requirements.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	―	116.00K
	Gross Profit
-11.00K	-12.00K	-12.00K	―	49.00K
	EBIT
-8.35M	-6.65M	-12.50M	-11.72M	-13.32M
	EBITDA
-8.77M	-6.52M	-12.49M	-11.71M	-13.12M
	Net Income Common Stockholders
-8.84M	-6.58M	-12.54M	-11.74M	-13.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
70.00K	1.40M	830.00K	3.61M	5.24M
	Total Assets
627.00K	1.63M	2.03M	4.93M	6.08M
	Total Debt
750.00K	173.00K	391.00K	426.00K	147.00K
	Net Debt
680.00K	-1.23M	-439.00K	-3.19M	-5.09M
	Total Liabilities
3.80M	2.11M	1.95M	2.20M	2.04M
	Stockholders Equity
-3.17M	-482.00K	83.00K	2.73M	4.04M
Cash Flow		Free Cash Flow
-4.06M	-5.21M	―	-10.05M	-7.43M
	Operating Cash Flow
-4.06M	-5.21M	-9.82M	-10.04M	-7.43M
	Investing Cash Flow
-3.00K	0.00	―	-13.00K	0.00
	Financing Cash Flow
2.73M	5.78M	7.04M	8.42M	4.72M

Nymox Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NYMXF, the sentiment is Neutral. The current price of 0.08 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.88 is Neutral, neither overbought nor oversold. The STOCH value of 93.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NYMXF.

Nymox Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATHE	51 Neutral	$39.86M	―	-154.88%	―	―	20.25%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
SCYX	42 Neutral	$33.57M	―	-33.25%	―	-97.33%	-136.16%
BCLI	32 Underperform	$7.27M	―	234.90%	―	―	62.35%
EPIX	32 Underperform	$67.47M	―	-23.98%	―	―	-19.93%
CYCC	28 Underperform	$47.07M	―	-807.39%	―	-89.76%	80.28%
NYMXF	22 Underperform	$11.18M	―	278.73%	―	―	―